A Safety and Immunogenicity Trial of IHV01

NCT02756208 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

HIV Infection

Interventions

BIOLOGICAL: 300 ug FLSC vaccine
BIOLOGICAL: 150 ug FLSC vaccine
BIOLOGICAL: 75 ug FLSC vaccine
BIOLOGICAL: Placebo

Sponsor

University of Maryland, Baltimore

Collaborators

[object Object]
[object Object]